Steve Bryson, PhD, science writer —

NovelMed has been cleared to begin patient testing of NM8074, an investigational antibody-based therapy for atypical hemolytic uremic syndrome (aHUS) that is not expected to carry a risk of treatment-related infections. The therapy candidate is designed to block the complement cascade — a part of the immune system…

Using Soliris (eculizumab) in combination with the blood cancer treatment obinutuzumab successfully prevented the recurrence of atypical hemolytic uremic syndrome (aHUS) after kidney transplant in a 45-year-old woman, a case study reported for the first time. The woman lost kidney function due to a rare occurrence of aHUS…

Proteins called factor Ba and sC5b-9 measured in the blood and urine of people with atypical hemolytic uremic syndrome (aHUS) showed they are clinically useful to mark features of the condition, a study showed. Thrombomodulin, a marker of blood vessel damage, and the inflammatory indicator sTNF-RI, combined with factor…

Soliris (eculizumab) safely and effectively treated chronic kidney disease in children with atypical hemolytic uremic syndrome (aHUS), a review study confirmed. Researchers suggested that more research is necessary, however, to establish its effectiveness, safety, and time of discontinuation in the long term. The review study, “The treatment…

Uterine fibroid surgery triggered atypical hemolytic uremic syndrome (aHUS) in a woman without disease-related genetic defects, a case study reported. Clinicians should investigate conditions such as aHUS after major gynecologic surgery accompanied by kidney impairment and abnormal lab tests indicating red blood cell damage to prevent irreversible kidney disease,…

A 26-year-old man developed atypical hemolytic uremic syndrome (aHUS) triggered by a lung infection and caused by a previously unreported genetic mutation, a case study described. According to researchers, his case highlights the importance of genetic testing for a definitive diagnosis of inherited aHUS. The case study, “A…

Relapses of Crohn’s disease, an inflammatory bowel condition, lessened the efficacy of Soliris (eculizumab) in an adolescent girl with atypical hemolytic uremic syndrome (aHUS), a case study reported. “Increased doses of [Soliris] may be necessary to maintain therapeutic blood levels of [Soliris] and full complement blockade, especially if…

Severe colon infection caused by the bacteria Clostridioides difficile triggered a rare case of atypical hemolytic uremic syndrome (aHUS) in a healthy young woman, a case study reported. She responded quickly to treatment with Soliris (eculizumab), its scientists noted, leading them to suggest this bacterial infection can be…

Ultomiris (ravulizumab) can safely and effectively treat women with atypical hemolytic uremic syndrome (aHUS) whose symptoms are triggered by pregnancy, a Phase 3 clinical trial analysis reveals.  The study, “Efficacy and safety of the long-acting…

A common mutation in the CD46 gene associated with atypical hemolytic uremic syndrome (aHUS) onset does not seem to be enough to trigger the disorder, as it occurs in both affected and unaffected family members, a genetic analysis shows.  Further analysis found evidence of an…